+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Breast Cancer Therapeutics Market 2019-2023 - Product Image

Global Breast Cancer Therapeutics Market 2019-2023

  • ID: 4721470
  • Report
  • December 2018
  • Region: Global
  • 137 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • MORE
Emerging novel therapies to gain traction in the market. Therapies including combination therapies, vaccines, PARP inhibitors, and CDK inhibitors are emerging as innovative approaches to treat breasts cancer. The analysts have predicted that the breast cancer therapeutics market will register a CAGR of close to 8% by 2023.

Market Overview

Rising number of patient supportive initiatives

To address the economic and emotional burden associated with cancer, manufacturers, governments, non-profit organizations, and healthcare providers are aiming at improving patient access to resources and bridge the substantial gaps in care.

Tendency of patients to prefer substitutes

Individuals with breast cancer often opt for mastectomy, lumpectomy, and radiation therapy to eliminate the tumor mass. However, efficient therapies including chemotherapy, and targeted and hormonal therapies are used to treat breast cancer. These surgeries act as substitutes and patients prefer these substitutes, which are expensive and can have a series of side effects.

For the detailed list of factors that will drive and challenge the growth of the breast cancer therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer, the competitive environment is quite intense. Factors such as the emerging novel therapies and the rising number of patient supportive initiatives, will provide considerable growth opportunities to breast cancer therapeutics manufactures. AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Hormonal therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • Ductal carcinoma in situ
  • Invasive Ductal Carcinoma
  • Triple-negative breast cancer
  • Inflammatory breast cancer
  • Metastatic breast cancer
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology drugs market
Exhibit 03: Segments of global oncology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Molecules in the pipeline for different type of breast cancer
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Sales in $ millions from 2015-2017
Exhibit 24: Hormonal therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Hormonal therapy - Year-over-year growth 2019-2023 (%)
Exhibit 26: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: First-in-class drugs for the treatment of breast cancer approved in 2017 and 2018
Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: New drug approvals for breast cancer
Exhibit 43: Patient support programs
Exhibit 44: Biosimilars for Herceptin and Avastin
Exhibit 45: Impact of drivers and challenges
Exhibit 46: List of collaborations between manufacturers for the breast cancer therapies
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca - Vendor overview
Exhibit 53: AstraZeneca - Business segments
Exhibit 54: AstraZeneca - Organizational developments
Exhibit 55: AstraZeneca - Geographic focus
Exhibit 56: AstraZeneca - Key offerings
Exhibit 57: Eli Lilly - Vendor overview
Exhibit 58: Eli Lilly - Business segments
Exhibit 59: Eli Lilly - Organizational developments
Exhibit 60: Eli Lilly - Geographic focus
Exhibit 61: Eli Lilly - Segment focus
Exhibit 62: Eli Lilly - Key offerings
Exhibit 63: F. Hoffmann-La Roche - Vendor overview
Exhibit 64: F. Hoffmann-La Roche - Business segments
Exhibit 65: F. Hoffmann-La Roche - Organizational developments
Exhibit 66: F. Hoffmann-La Roche - Geographic focus
Exhibit 67: F. Hoffmann-La Roche - Segment focus
Exhibit 68: F. Hoffmann-La Roche - Key offerings
Exhibit 69: Novartis - Vendor overview
Exhibit 70: Novartis - Business segments
Exhibit 71: Novartis - Organizational developments
Exhibit 72: Novartis - Geographic focus
Exhibit 73: Novartis - Segment focus
Exhibit 74: Novartis - Key offerings
Exhibit 75: Pfizer - Vendor overview
Exhibit 76: Pfizer - Business segments
Exhibit 77: Pfizer - Organizational developments
Exhibit 78: Pfizer - Geographic focus
Exhibit 79: Pfizer - Segment focus
Exhibit 80: Pfizer - Key offerings
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • MORE
Global breast cancer therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global breast cancer therapeutics market: AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis, and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emerging novel therapies.”

According to the report, one of the major drivers for this market is the rising number of patient supportive initiatives.

Further, the report states that one of the major factors hindering the growth of this market is the tendency of patients to prefer substitutes

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll